Status:
COMPLETED
Primaquine's Gametocytocidal Efficacy in Malaria Asymptomatic Carriers
Lead Sponsor:
London School of Hygiene and Tropical Medicine
Conditions:
Malaria
Eligibility:
All Genders
12+ years
Phase:
PHASE3
Brief Summary
In this study, the investigators are interested to know if lower doses of Primaquine together with dihydroartemisinin-piperaquine can produce a similar effect of clearing both sexual and asexual paras...
Detailed Description
To date, primaquine (PQ), an 8-aminoquinoline, is the only currently registered product able to clear P. falciparum mature gametocytes. However, its use has been and is still limited by its haematolog...
Eligibility Criteria
Inclusion
- Age ≥1 year
- Weight \>10 Kg
- P. falciparum mono-infection, density of at least 20 parasites/μL
- Axillary temperature \< 37.5ºC
- Resident in the study area and willingness to reside for the duration of the study
- Written informed consent (plus an assent in children \>12years of age)
Exclusion
- G6PD Deficiency Haemoglobin \<8g/dl
- Known allergy to any of the study medications
- Known Pregnancy or breastfeeding
- Clear/documented history of anti-malarial treatment 2 weeks before contact with study team
- History of blood transfusion in the previous 3 months
- Any chronic or acute conditions that might interfere with the study as judged by the research clinician
- History of sickle cell anaemia
Key Trial Info
Start Date :
August 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2015
Estimated Enrollment :
467 Patients enrolled
Trial Details
Trial ID
NCT01838902
Start Date
August 1 2013
End Date
October 1 2015
Last Update
March 22 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical Research Council Unit (MRC), The Gambia
Fajara, The Gambia